{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:57:31Z","timestamp":1792879051933,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41380-022-01770-w","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T09:03:09Z","timestamp":1663837389000},"page":"369-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-3936","authenticated-orcid":false,"given":"Giovanni","family":"Croatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davy","family":"Vancampfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Miola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-0539","authenticated-orcid":false,"given":"Miriam","family":"Olivola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-4071","authenticated-orcid":false,"given":"Jess G.","family":"Fiedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Firth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Alexinschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-9014","authenticated-orcid":false,"given":"Marcel A.","family":"Gaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Makkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Cunha","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-4079","authenticated-orcid":false,"given":"Leandro","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-6788","authenticated-orcid":false,"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2500-5671","authenticated-orcid":false,"given":"Andre F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-1820","authenticated-orcid":false,"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"1770_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpsychires.2020.03.015","volume":"125","author":"H He","year":"2020","unstructured":"He H, Hu C, Ren Z, Bai L, Gao F, Lyu J. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: Results from the global burden of Disease Study 2017. J Psychiatr Res. 2020;125:96\u2013105.","journal-title":"J Psychiatr Res"},{"key":"1770_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"AF Carvalho","year":"2020","unstructured":"Carvalho AF, Firth J, Vieta E. Bipolar disorder. N. Engl J Med. 2020;383:58\u201366.","journal-title":"N. Engl J Med"},{"key":"1770_CR3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V). Washington: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1770_CR4","doi-asserted-by":"publisher","unstructured":"Carlborg A, Ferntoft L, Thuresson M, Bodegard J Population study of disease burden, management, and treatment of bipolar disorder in Sweden: A retrospective observational registry study. Bipolar Disord. 2015. 2015. https:\/\/doi.org\/10.1111\/bdi.12234.","DOI":"10.1111\/bdi.12234"},{"key":"1770_CR5","doi-asserted-by":"publisher","unstructured":"Kessing LV, Vradi E, McIntyre RS, Andersen PK. Causes of decreased life expectancy over the life span in bipolar disorder. J Affect Disord. 2015. 2015. https:\/\/doi.org\/10.1016\/j.jad.2015.03.027.","DOI":"10.1016\/j.jad.2015.03.027"},{"key":"1770_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bdi.12373","volume":"18","author":"JD Rosenblat","year":"2016","unstructured":"Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, et al. Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-analysis. Bipolar Disord. 2016;18:89\u2013101.","journal-title":"Bipolar Disord"},{"key":"1770_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","volume":"15","author":"D Vancampfort","year":"2016","unstructured":"Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166\u2013174.","journal-title":"World Psychiatry"},{"key":"1770_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339\u2013347.","journal-title":"World Psychiatry"},{"key":"1770_CR9","doi-asserted-by":"crossref","unstructured":"Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163\u201380.","DOI":"10.1002\/wps.20420"},{"key":"1770_CR10","doi-asserted-by":"publisher","unstructured":"Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2020. 2020. https:\/\/doi.org\/10.1038\/s41569-020-00463-7.","DOI":"10.1038\/s41569-020-00463-7"},{"key":"1770_CR11","doi-asserted-by":"publisher","unstructured":"Laursen TM, Wahlbeck K, H\u00e4llgren J, Westman J, \u00d6sby U, Alinaghizadeh H, et al. Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in the Nordic Countries. PLoS One. 2013. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0067133.","DOI":"10.1371\/journal.pone.0067133"},{"key":"1770_CR12","doi-asserted-by":"crossref","unstructured":"Fenn HH. Treatment of bipolarity+medical comorbidity=costability: An editorial comment to Magalhaes PV, Kapczinski F, Nierenberg AA, Deckersback T, Weisinger D, Dodd S, Berk M. Illness burden and medical comorbidity in the Systemic Treatment Enhancement Program fo. Acta Psychiatr Scand. 2012;125:262\u20133.","DOI":"10.1111\/j.1600-0447.2011.01804.x"},{"key":"1770_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bdi.12243","volume":"17","author":"LG Sylvia","year":"2015","unstructured":"Sylvia LG, Shelton RC, Kemp DE, Bernstein EE, Friedman ES, Brody BD, et al. Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord. 2015;17:212\u2013223.","journal-title":"Bipolar Disord"},{"key":"1770_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.261","volume":"7","author":"AT Amare","year":"2017","unstructured":"Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7:e1007.","journal-title":"Transl Psychiatry"},{"key":"1770_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00127-016-1171-1","volume":"51","author":"P Hyland","year":"2016","unstructured":"Hyland P, Shevlin M, Elklit A, Christoffersen M, Murphy J. Social, familial and psychological risk factors for mood and anxiety disorders in childhood and early adulthood: a birth cohort study using the Danish Registry System. Soc Psychiatry Psychiatr Epidemiol. 2016;51:331\u2013338.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"1770_CR16","doi-asserted-by":"publisher","first-page":"113514","DOI":"10.1016\/j.psychres.2020.113514","volume":"294","author":"C Park","year":"2020","unstructured":"Park C, Majeed A, Gill H, Tamura J, Ho RC, Mansur RB, et al. The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. Psychiatry Res. 2020;294:113514.","journal-title":"Psychiatry Res"},{"key":"1770_CR17","doi-asserted-by":"crossref","unstructured":"Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental illness. The Lancet Psychiatry. 2019;6:675\u2013712.","DOI":"10.1016\/S2215-0366(19)30387-6"},{"key":"1770_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/wps.20458","volume":"16","author":"D Vancampfort","year":"2017","unstructured":"Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry. 2017;16:308\u2013315.","journal-title":"World Psychiatry"},{"key":"1770_CR19","doi-asserted-by":"crossref","unstructured":"Beyer JL, Payne ME. Nutrition and Bipolar Depression. Psychiatr Clin North Am. 2016;39:75\u201386.","DOI":"10.1016\/j.psc.2015.10.003"},{"key":"1770_CR20","doi-asserted-by":"publisher","unstructured":"Li XH, An FR, Ungvari GS, Ng CH, Chiu HFK, Wu PP, et al. Prevalence of smoking in patients with bipolar disorder, major depressive disorder and schizophrenia and their relationships with quality of life. Sci Rep. 2017. 2017. https:\/\/doi.org\/10.1038\/s41598-017-07928-9.","DOI":"10.1038\/s41598-017-07928-9"},{"key":"1770_CR21","doi-asserted-by":"publisher","unstructured":"Castillo MA, Rincon VMC, Serna HV, Bersh S Alcohol Consumption and Bipolar Disorder in a Colombian Population Sample. Rev Colomb Psiquiatr. 2020. 2020. https:\/\/doi.org\/10.1016\/j.rcp.2018.03.003.","DOI":"10.1016\/j.rcp.2018.03.003"},{"key":"1770_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64\u201377.","journal-title":"Lancet Psychiatry"},{"key":"1770_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti\u2010attention\u2010deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: A large scale systematic meta\u2010review of 78 adverse effects. World Psychiatry. 2020;19:214\u2013232.","journal-title":"World Psychiatry"},{"key":"1770_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first-and second-generation antipsychotics: A state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757\u2013777.","journal-title":"Ther Clin Risk Manag"},{"key":"1770_CR25","doi-asserted-by":"publisher","unstructured":"Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015. 2015. https:\/\/doi.org\/10.1002\/wps.20204.","DOI":"10.1002\/wps.20204"},{"key":"1770_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","volume":"19","author":"H Taipale","year":"2020","unstructured":"Taipale H, Tanskanen A, Meht\u00e4l\u00e4 J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19:61\u201368.","journal-title":"World Psychiatry"},{"key":"1770_CR27","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jamapsychiatry.2019.2859","volume":"76","author":"E Dragioti","year":"2019","unstructured":"Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et al. Association of Antidepressant Use with Adverse Health Outcomes: A Systematic Umbrella Review. JAMA Psychiatry. 2019;76:1241\u20131255.","journal-title":"JAMA Psychiatry"},{"key":"1770_CR28","doi-asserted-by":"crossref","unstructured":"Vancampfort D, Firth J, Correll CU, Solmi M, Siskind D, De Hert M, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18:53\u201366.","DOI":"10.1002\/wps.20614"},{"key":"1770_CR29","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jamda.2020.01.010","volume":"21","author":"D Vancampfort","year":"2020","unstructured":"Vancampfort D, Solmi M, Firth J, Vandenbulcke M, Stubbs B. The Impact of Pharmacologic and Nonpharmacologic Interventions to Improve Physical Health Outcomes in People With Dementia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials. J Am Med Dir Assoc. 2020;21:1410\u20131414.e2.","journal-title":"J Am Med Dir Assoc"},{"key":"1770_CR30","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"1770_CR31","doi-asserted-by":"crossref","unstructured":"Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7.","DOI":"10.1186\/1471-2288-7-10"},{"key":"1770_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","volume":"74","author":"CU Correll","year":"2017","unstructured":"Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74:675\u2013684.","journal-title":"JAMA Psychiatry"},{"key":"1770_CR33","doi-asserted-by":"crossref","unstructured":"Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021;20:244\u201375.","DOI":"10.1002\/wps.20881"},{"key":"1770_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.282.16.1547","volume":"282","author":"M Wei","year":"1999","unstructured":"Wei M, Kampert JB, Barlow CE, Nichaman MZ, Gibbons LW, Ralph S, Paffenbarger J, et al. Relationship Between Low Cardiorespiratory Fitness and Mortality in Normal-Weight, Overweight, and Obese Men. JAMA 1999;282:1547.","journal-title":"JAMA"},{"key":"1770_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.psychres.2017.06.066","volume":"256","author":"D Vancampfort","year":"2017","unstructured":"Vancampfort D, Hagemann N, Wyckaert S, Rosenbaum S, Stubbs B, Firth J, et al. Higher cardio-respiratory fitness is associated with increased mental and physical quality of life in people with bipolar disorder: A controlled pilot study. Psychiatry Res. 2017;256:219\u2013224.","journal-title":"Psychiatry Res"},{"key":"1770_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ypmed.2016.10.011","volume":"93","author":"FB Schuch","year":"2016","unstructured":"Schuch FB, Vancampfort D, Sui X, Rosenbaum S, Firth J, Richards J, et al. Are lower levels of cardiorespiratory fitness associated with incident depression? A systematic review of prospective cohort studies. Prev Med (Balt). 2016;93:159\u2013165.","journal-title":"Prev Med (Balt)"},{"key":"1770_CR37","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.4088\/JCP.15m10474","volume":"78","author":"SE Baumeister","year":"2017","unstructured":"Baumeister SE, Leitzmann MF, Bahls M, D\u00f6rr M, Schmid D, Schomerus G, et al. Associations of Leisure-Time and Occupational Physical Activity and Cardiorespiratory Fitness With Incident and Recurrent Major Depressive Disorder, Depressive Symptoms, and Incident Anxiety in a General Population. J Clin Psychiatry. 2017;78:e41\u2013e47.","journal-title":"J Clin Psychiatry"},{"key":"1770_CR38","doi-asserted-by":"crossref","unstructured":"Cernea S, Dima L, Correll CU, Manu P. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs. 2020;80:1763\u201381.","DOI":"10.1007\/s40265-020-01393-x"},{"key":"1770_CR39","doi-asserted-by":"crossref","unstructured":"Fornaro M, De Prisco M, Billeci M, Ermini E, Young AH, Lafer B, et al. Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. J Affect Disord. 2021;295:740\u201351.","DOI":"10.1016\/j.jad.2021.08.091"},{"key":"1770_CR40","unstructured":"Recommendations|Depression in adults: recognition and management|Guidance|NICE."},{"key":"1770_CR41","unstructured":"Overview|Depression in adults with a chronic physical health problem: recognition and management|Guidance|NICE."},{"key":"1770_CR42","doi-asserted-by":"crossref","unstructured":"Jobst A, Brakemeier EL, Buchheim A, Caspar F, Cuijpers P, Ebmeier KP, et al. European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe. Eur Psychiatry. 2016;33:18\u201336.","DOI":"10.1016\/j.eurpsy.2015.12.003"},{"key":"1770_CR43","doi-asserted-by":"crossref","unstructured":"M\u00f6ller HJ, Bitter I, Bobes J, Fountoulakis K, H\u00f6schl C, Kasper S. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. Eur Psychiatry. 2012;27:114\u201328.","DOI":"10.1016\/j.eurpsy.2011.08.002"},{"key":"1770_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61:540\u2013560.","journal-title":"Can J Psychiatry"},{"key":"1770_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0706743716659418","volume":"61","author":"SV Parikh","year":"2016","unstructured":"Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. Can J Psychiatry. 2016;61:524\u2013539.","journal-title":"Can J Psychiatry"},{"key":"1770_CR46","first-page":"91","volume":"24","author":"R Ramasubbu","year":"2012","unstructured":"Ramasubbu R, Taylor VH, Samaan Z, Sockalingham S, Li M, Patten S, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012;24:91\u2013109.","journal-title":"Ann Clin Psychiatry"},{"key":"1770_CR47","doi-asserted-by":"crossref","unstructured":"Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018;54:124\u201344.","DOI":"10.1016\/j.eurpsy.2018.07.004"},{"key":"1770_CR48","unstructured":"Overview|Bipolar disorder: assessment and management|Guidance|NICE."},{"key":"1770_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97\u2013170.","journal-title":"Bipolar Disord"},{"key":"1770_CR50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/wps.20773","volume":"19","author":"J Firth","year":"2020","unstructured":"Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, et al. A meta-review of \u2018lifestyle psychiatry\u2019: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19:360\u2013380.","journal-title":"World Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01770-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:17:44Z","timestamp":1744204664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01770-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1038\/s41380-022-01770-w","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Marco Solmi received honoraria\/has been a consultant for Angelini, Lundbeck, Otsuka. Dr. Correll has been a consultant and\/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris.. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. Dr. Firth has received honoraria \/ consultancy fees from Atheneum, ParachuteBH and Nirakara, independent of this work. All other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}